Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Bradley Somer (NPI 1851320691)

Field	Value
Entity Type	Individual
Organization	Bradley Somer
Address	7945 Wolf River Blvd
City	Germantown
State	TN
ZIP	38138
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 2, 2006

Payer Source	Total Paid
Medicare	$2.8M
Medicaid	$0

Key Findings

This provider is effectively single‑payer with total Medicare revenue of $2.8M and no Medicaid billing on file, indicating nearly all reimbursement exposure comes from Medicare. The NPI was enumerated 2006-07-02 (~20 years ago), which suggests an established practice footprint that is largely oriented to the Medicare population.

Revenue is highly concentrated in a small set of immunotherapy and biologic codes: the precomputed top‑3 Medicare codes account for 65.5% of this provider's total Medicare revenue, with J9271 generating $907.3K (33.3%), J9299 generating $678.7K (24.9%), and J9144 generating $198.4K (7.3%). This degree of concentration means a few high‑cost drug administrations drive the bulk of reimbursement.

The CPT/HCPCS mix indicates an infusion‑based oncology practice that centers on checkpoint inhibitors and monoclonal antibodies: J9271 (pembrolizumab), J9299 (nivolumab), J9144 (daratumumab), and J9173 (durvalumab) are the top revenue contributors, supported by chemotherapy administration 96413 and infusion add‑on codes such as 96367. Presence of agents like J0897 (denosumab), J2506 (pegfilgrastim), and immune globulin J1569 further signals integrated cancer care with marrow support and bone‑health management.

Competitive standing on the top immunotherapy codes is mixed: J9271 ranks #344 of 1841 nationally (81th percentile; typical, unremarkable volume for this code) and J9299 ranks #89 of 505 nationally (83th percentile; typical, unremarkable volume for this code), indicating mid‑tier national presence for these high‑value agents, while J9144 ranks #477 of 615 (22th percentile; typical, unremarkable volume for this code) and J9173 ranks #40 of 53 (25th percentile; typical, unremarkable volume for this code), which suggests more modest or niche activity for some monoclonals. These rank/percentile patterns imply the provider is not a dominant national outlier but maintains meaningful volume in a subset of immunotherapies.

Operational signals point to substantial in‑office service capacity: evaluation/management codes 99213 (633 claims, $38.6K revenue) and 99205 (104 claims, $16.2K revenue) are described as "notably above typical national volume" (99213 ranks #17507 of 457151, 96th percentile; 99205 ranks #2832 of 66257, 96th percentile), while high percentiles on routine lab and phlebotomy codes—85025 (2.6K claims, $20.5K revenue; 98th percentile), 80048 (2.4K claims, $19.2K revenue; 98th percentile), 80076 (2.3K claims, $18.4K revenue; 97th percentile), and 36415 (2.1K claims, $16.4K revenue; 99th percentile)—underscore substantial on‑site specimen collection and lab throughput. Together these patterns are consistent with a practice that delivers and bills for frequent infusions plus associated office visits and labs.

The provider shows selective use of biosimilars and lower‑share agents: Q5123 (rituximab‑arrx) generates $43.7K and ranks #36 of 40 nationally (10th percentile; typical, unremarkable volume for this code) and Q5107 (bevacizumab‑awwb) generates $39.3K and ranks #59 of 78 (25th percentile; typical, unremarkable volume for this code). These low percentile ranks for certain biosimilars suggest limited national footprint for those specific products relative to peers, even as branded immunotherapies drive overall revenue.

Given that single codes (J9271 and J9299) each account for large single‑code dollar amounts—$907.3K and $678.7K respectively—the practice faces concentrated revenue risk tied to utilization and reimbursement of a small set of high‑cost biologics. Payers and network analysts should note that changes in access, prior‑authorization, or price for these agents could disproportionately affect this provider's Medicare revenue stream.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

96 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,100	$40	$907.3K
J9299	Injection, nivolumab, 1 mg	28,280	$20	$678.7K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	5,220	$40	$198.4K
J9173	Injection, durvalumab, 10 mg	2,910	$60	$180.4K
J0897	Injection, denosumab, 1 mg	6,900	$20	$124.2K
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	650	$160	$100.8K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	1,370	$40	$49.3K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	540	$90	$49.1K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	520	$90	$45.9K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$90	$44.4K

Showing 1–10 of 96

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 96 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Bradley Somer — 6 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

96 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	50	17,400	$40	$776.1K
J9299	4	20	21,010	$20	$487.5K
J9144	19	20	10,080	$40	$466.3K
J9173	4	10	3,720	$60	$211.7K
J1569	25	30	3,030	$40	$175.2K
J2353	3	10	650	$150	$106.3K
J0897	48	240	2,940	$20	$85K
Q5107	15	20	2,990	$20	$77.6K
Q5123	12	10	1,960	$40	$70.9K
J0881	38	70	19,050	$1	$54.4K

Showing 1–10 of 96

Related Providers

Other providers that share a Tax Identification Number (TIN) with Bradley Somer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Shelby County Health Care Corporation	TN	General Acute Care Hospital	$0	$56.1M
The West Clinic P.C.	TN	Specialist	$0	$16M
David Portnoy	TN	Hematology & Oncology Physician	$6.5M	$0
Kurt Tauer	TN	Medical Oncology Physician	$3.9M	$0
Gang Tian	TN	Hematology & Oncology Physician	$3.8M	$0
Jason Chandler	TN	Medical Oncology Physician	$3.8M	$0
Syed Sameer Nasir	TN	Hematology & Oncology Physician	$3.5M	$0
Ramakrishna Battini	TN	Hematology & Oncology Physician	$3.3M	$0
Eric Wiedower	TN	Hematology & Oncology Physician	$2.9M	$0
Robert Johnson	TN	Hematology & Oncology Physician	$2.8M	$0

Nearby Providers

Other providers in the same ZIP code as Bradley Somer, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Byram Healthcare Centers, Inc.	TN	Durable Medical Equipment & Medical Supplies	$0	$44.3M
Campbell Clinic, PC	TN	Orthopaedic Surgery Physician	$0	$28M
Poplar Avenue Clinic PLLC	TN	Gynecologic Oncology Physician	$0	$9.7M
Diagnostic Ultrasound Consultants	TN	Diagnostic Radiology Physician	$0	$8.5M
Mid-south Imaging & Therapeutics, P.A.	TN	Diagnostic Radiology Physician	$0	$8.2M
Stephen Huddleston	TN	Retina Specialist (Ophthalmology) Physician	$5.7M	$0
Stern Cardiovascular Foundation, Inc	TN	Cardiovascular Disease Physician	$0	$4.7M
G I Diagnostic And Therapeutic Center LLC	TN	Endoscopy Clinic/Center	$4.2M	$8.6K
Memphis Neurology PLLC	TN	Neurology Physician	$0	$3.9M
Raza Hashmi	TN	Rheumatology Physician	$3.9M	$0

Bradley Somer — Billing Profile & Reimbursement Data

Sign up for Bradley Somer — Billing Profile & Reimbursement Data policy alerts

Bradley Somer — Billing Profile & Reimbursement Data

Sign up for Bradley Somer — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References